ZUNVEYL Drug Patent Profile
✉ Email this page to a colleague
When do Zunveyl patents expire, and what generic alternatives are available?
Zunveyl is a drug marketed by Alpha Cognition and is included in one NDA. There are two patents protecting this drug.
This drug has twenty-four patent family members in seventeen countries.
The generic ingredient in ZUNVEYL is benzgalantamine gluconate. One supplier is listed for this compound. Additional details are available on the benzgalantamine gluconate profile page.
DrugPatentWatch® Generic Entry Outlook for Zunveyl
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be May 16, 2027. This may change due to patent challenges or generic licensing.
Indicators of Generic Entry
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for ZUNVEYL?
- What are the global sales for ZUNVEYL?
- What is Average Wholesale Price for ZUNVEYL?
Summary for ZUNVEYL
| International Patents: | 24 |
| US Patents: | 2 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| What excipients (inactive ingredients) are in ZUNVEYL? | ZUNVEYL excipients list |
| DailyMed Link: | ZUNVEYL at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for ZUNVEYL
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
US Patents and Regulatory Information for ZUNVEYL
ZUNVEYL is protected by two US patents.
Based on analysis by DrugPatentWatch, the earliest date for a generic version of ZUNVEYL is ⤷ Sign Up.
This potential generic entry date is based on patent ⤷ Sign Up.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
Patents protecting ZUNVEYL
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF MILD TO MODERATE DEMENTIA OF THE ALZHEIMER'S TYPE
Cholinergic enhancers with improved blood-brain barrier permeability for the treatment of diseases accompanied by cognitive impairment
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF MILD TO MODERATE DEMENTIA OF THE ALZHEIMER'S TYPE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Alpha Cognition | ZUNVEYL | benzgalantamine gluconate | TABLET, DELAYED RELEASE;ORAL | 218549-001 | Jul 26, 2024 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Alpha Cognition | ZUNVEYL | benzgalantamine gluconate | TABLET, DELAYED RELEASE;ORAL | 218549-002 | Jul 26, 2024 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Alpha Cognition | ZUNVEYL | benzgalantamine gluconate | TABLET, DELAYED RELEASE;ORAL | 218549-001 | Jul 26, 2024 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for ZUNVEYL
When does loss-of-exclusivity occur for ZUNVEYL?
Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:
Austria
Patent: 73219
Estimated Expiration: ⤷ Sign Up
Canada
Patent: 23114
Patent: AMPLIFICATEURS CHOLINERGIQUES DE PERMEABILITE DE LA BARRIERE SANG-CERVEAU AMELIOREE POUR LE TRAITEMENT DE MALADIES ACCOMPAGNEES D'UNE DEFICIENCE COGNITIVE (CHOLINERGIC ENHANCERS WITH IMPROVED BLOOD-BRAIN BARRIER PERMEABILITY FOR THE TREATMENT OF DISEASES ACCOMPANIED BY COGNITIVE IMPAIRMENT)
Estimated Expiration: ⤷ Sign Up
China
Patent: 1287719
Patent: Cholinergic enhancers with improved blood-brain barrier permeability for the treatment of diseases accompanied by cognitive impairment
Estimated Expiration: ⤷ Sign Up
Cyprus
Patent: 10822
Estimated Expiration: ⤷ Sign Up
Denmark
Patent: 40817
Estimated Expiration: ⤷ Sign Up
European Patent Office
Patent: 77222
Patent: Inhibiteurs de la cholinesterase avec une perméabilité améliorée de la barrière ématoencéphalique pour le traitement de troubles cognitifs (Cholinergic enhancers with improved blood-brain barrier permeability for the treatment of diseases accompanied by cognitive impairment)
Estimated Expiration: ⤷ Sign Up
Patent: 40817
Patent: AMPLIFICATEURS CHOLINERGIQUES DE PERMÉABILITÉ DE LA BARRIÈRE SANG-CERVEAU AMÉLIORÉE POUR LE TRAITEMENT DE MALADIES ACCOMPAGNÉES D'UNE DÉFICIENCE COGNITIVE (CHOLINERGIC ENHANCERS WITH IMPROVED BLOOD-BRAIN BARRIER PERMEABILITY FOR THE TREATMENT OF DISEASES ACCOMPANIED BY COGNITIVE IMPAIRMENT)
Estimated Expiration: ⤷ Sign Up
Germany
Patent: 2006015338
Estimated Expiration: ⤷ Sign Up
Japan
Patent: 09508903
Estimated Expiration: ⤷ Sign Up
Poland
Patent: 40817
Estimated Expiration: ⤷ Sign Up
Portugal
Patent: 40817
Estimated Expiration: ⤷ Sign Up
Slovenia
Patent: 40817
Estimated Expiration: ⤷ Sign Up
Spain
Patent: 48334
Estimated Expiration: ⤷ Sign Up
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
See the table below for additional patents covering ZUNVEYL around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Portugal | 1940817 | ⤷ Sign Up | |
| Canada | 2623114 | AMPLIFICATEURS CHOLINERGIQUES DE PERMEABILITE DE LA BARRIERE SANG-CERVEAU AMELIOREE POUR LE TRAITEMENT DE MALADIES ACCOMPAGNEES D'UNE DEFICIENCE COGNITIVE (CHOLINERGIC ENHANCERS WITH IMPROVED BLOOD-BRAIN BARRIER PERMEABILITY FOR THE TREATMENT OF DISEASES ACCOMPANIED BY COGNITIVE IMPAIRMENT) | ⤷ Sign Up |
| China | 101287719 | Cholinergic enhancers with improved blood-brain barrier permeability for the treatment of diseases accompanied by cognitive impairment | ⤷ Sign Up |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
